Founded in 1986 in Yichang, China, Angel Yeast has grown from a single-plant operation into one of the world's largest yeast producers, now supplying ingredients and biotechnology products to more than 170 countries. As the company marks its 40th anniversary, Chairman Xiong Tao spoke to Food Ingredients First about the trajectory that brought it here and where it intends to go next.

From staple ingredient to functional platform

Angel Yeast's commercial foundation remains yeast for baking. A category in which it has pursued large-scale production to drive down costs and extend availability to markets where commercially produced yeast was previously scarce or expensive. That base has since broadened considerably. The company now operates across four principal areas: baking yeast, savoury yeast extracts, nutrition and health ingredients and biotechnology.

Within the nutrition segment, the standout product is Angeopro, a yeast-derived protein with a declared protein content exceeding 80%. Angel Yeast positions this as a fermentation-based alternative protein suitable for sports nutrition, foods for special medical purposes and plant-based or vegan formulations. Sectors where demand for non-animal protein sources has grown markedly in recent years.

"Yeast protein is becoming a new fermented protein source for the nutrition industry," said Xiong Tao. "It is moving toward large-scale application, expanding from traditional sectors such as baking, meat products, and dairy to emerging areas such as sports nutrition, foods for special medical purposes, and vegan foods."

Yeast extracts and clean-label reformulation

In savoury ingredients, Angel Yeast applies biotechnology processes to produce yeast extracts used as flavouring agents and taste enhancers. The company describes these as tools for food manufacturers seeking to reformulate products, reducing added salt or monosodium glutamate while maintaining flavour profiles. Demand for such solutions has intensified as regulatory and consumer pressure around sodium reduction has increased across European markets in particular.

EcoVadis rating and the circular production model

In 2025, Angel Yeast received an EcoVadis Silver rating, placing it within the top 15% of organisations assessed by the platform across all sectors. The company has established what it describes as a circular production model: agricultural raw materials enter the production process and are converted into food ingredients, while manufacturing byproducts are processed into value-added outputs returned to agricultural use, including animal feed and fertiliser applications.

On the energy side, Angel Yeast has introduced solar and biomass energy sources across its facilities and developed a carbon footprint management system covering the full production lifecycle. The company has not disclosed specific reduction targets or verified emissions data publicly, but the EcoVadis rating provides third-party corroboration of its environmental management practices.

Europe and South-East Asia in the expansion plan

Two infrastructure investments are currently under way. Angel Yeast has established an R&D centre in Belgium, intended to support product development tailored to European market requirements, both regulatory and consumer taste preferences. A manufacturing facility is also under construction in Indonesia, with the stated aim of shortening supply chains for customers in South-East Asia and adjacent markets.

Xiong Tao framed the overseas strategy as one of genuine localisation rather than export expansion:

"We will continue our overseas development philosophy of 'localising for the local market,' bringing our supply chain closer to customers while also creating local jobs and supporting technological upgrading and industrial development."

The company currently operates 12 holding subsidiaries. It has not specified a timeline for the Indonesia facility's completion or the full scope of the Belgian R&D centre's activity.

With 40 years of yeast fermentation behind it, Angel Yeast's near-term priorities appear to be consolidating manufacturing capacity in growth regions, building out its protein and extract portfolios, and strengthening the R&D infrastructure needed to compete in technically demanding segments. How quickly Angeopro scales beyond its current markets and how the Belgian centre performs in product development terms, will be two indicators worth watching over the next few years.

Image copyright angelyeast.com: Xiong Tao, Chairman of Angel Yeast